CATB:NSD-Catabasis Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 2.74

Change

+0.15 (+5.79)%

Market Cap

USD 0.05B

Volume

1.16M

Average Target Price

USD 25.04 (+813.78%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. Its lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). The company is also developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a preclinical research collaboration with the Jain Foundation to study edasalonexent in dysferlinopathy; and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in drug-sensitive and drug-resistant tuberculosis. The company was founded in 2008 and is based in Boston, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+1.94 (+0.82%)

USD61.55B 23.20 18.26
REGN Regeneron Pharmaceuticals, Inc

-6.79 (-1.25%)

USD57.86B 19.87 14.64
MRNA Moderna, Inc

+7.84 (+6.26%)

USD49.52B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

+0.12 (+0.08%)

USD34.50B 36.61 33.83
SGEN Seagen Inc

-5.02 (-2.63%)

USD34.15B 72.05 70.76
BGNE BeiGene, Ltd

-5.81 (-1.60%)

USD33.65B N/A N/A
RPRX Royalty Pharma plc

+0.07 (+0.14%)

USD31.48B 22.60 11.90
GMAB Genmab A/S

-0.19 (-0.44%)

USD28.72B 26.59 3.08
BNTX BioNTech SE

+2.20 (+2.13%)

USD25.21B -99,999.99 N/A
INCY Incyte Corporation

-2.47 (-2.56%)

USD21.10B 47.64 35.20

ETFs Containing CATB

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 28.04% 75% C 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 28.04% 75% C 86% B
Trailing 12 Months  
Capital Gain -57.91% 6% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -57.91% 6% F 3% F
Trailing 5 Years  
Capital Gain -95.28% 10% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -95.28% 10% F 2% F
Average Annual (5 Year Horizon)  
Capital Gain -35.16% 6% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -35.16% 6% F 2% F
Risk Return Profile  
Volatility (Standard Deviation) 34.99% 74% C 40% F
Risk Adjusted Return -100.48% 6% F 3% F
Market Capitalization 0.05B 10% F 14% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.96 98% A+ 85% B
Price / Cash Flow Ratio -1.96 17% F 62% D-
EV/EBITDA 0.12 70% C- 95% A
Management Effectiveness  
Return on Equity -79.77% 39% F 14% F
Return on Invested Capital -76.67% 38% F 12% F
Return on Assets -43.71% 21% F 6% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.16 92% A- 91% A-
Short Percent 10.12% 32% F 21% F
Beta 2.19 20% F 11% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.